Exploiting regulatory T-cell populations for the immunotherapy of cancer

Journal of Immunotherapy

Volumn 30, Issue 6, 2007, Pages 591-595

  Van Der Vliet, Hans J J ^a,b   Koon, Henry B ^a   Atkins, Michael B ^a   Balk, Steven P ^a   Exley, Mark A ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Cancer; Immunotherapy; NKT cells; Regulatory T cells

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENILEUKIN DIFTITOX; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; MESSENGER RNA;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; HUMAN; KIDNEY CARCINOMA; LYMPHOCYTE FUNCTION; NATURAL KILLER T CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE DRUG DOSE; TUMOR ESCAPE;

CD4-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

EID: 34547748314     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31805ca058     Document Type: Review

References (61)

1. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer. 2004;4:401-411.
2. Ribas A, Butterfield LH, Glaspy JA, et al. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol. 2003;21:2415-2432.
3. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137-148.
4. Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol. 2004;22:1136-1151.
5. Kronenberg M, Rudensky A. Regulation of immunity by selfreactive T cells. Nature. 2005;435:598-604.
6. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:45-352.
7. + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med. 2005;201:779-791.
8. Terabe M, Berzofsky JA. Immunoregulatory T cells in tumor immunity. Curr Opin Immunol. 2004;16:157-162.
9. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61:4766-4772.
10. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756-2761.
11. + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer. 2003;98:1089-1099.
12. + suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother. 2003;26:85-93.
13. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103:1755-1762.
14. + regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004;173:1444-1453.
15. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-949.
16. high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother. 2005;55:1064-1071.
17. high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 2006;177:7398-7405.
18. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24:5373-5380.
19. Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12:5423-5434.
20. Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 2006;107:2866-2872.
21. Lizee G, Radvanyi LG, Overwijk WW, et al. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res. 2006;12:4794-4803.
22. Dudley ME, Wunderlich JR, Robbins PJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
23. Robbins PF, Dudley ME, Wunderlich J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 2004;173:7125-7130.
24. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA. 2004;101:14639-14645.
25. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005;202:907-912.
26. Frankel AE, Fleming DR, Hall PD, et al. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabinerefractory chronic lymphocytic leukemia. Clin Cancer Res. 2003;9:3555-3561.
27. Morgan SJ, Seymour JF, Prince HM, et al. Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression. Clin Cancer Res. 2004;10:3572-3575.
28. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005;115:3623-3633.
29. Attia P, Maker AV, Haworth LR, et al. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother. 2005;28:582-592.
30. Attia P, Powell DJ, Maker AV, et al. Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J Immunother. 2006;29:208-214.
31. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192:303-310.
32. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA. 2003;100:4712-4717.
33. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005;23:741-750.
34. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005;23:8926-8928.
35. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372-8377.
36. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol. 2005;175:7746-7754.
37. O'Mahony D, Janik JE. Comment on "Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade". J Immunol. 2006;176:5136.
38. Smyth MJ, Crowe NY, Hayakawa Y, et al. NKT cells-conductors of tumor immunity? Curr Opin Immunol. 2002;14:165-171.
39. Takeda K, Hayakawa Y, Atsuta M, et al. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. Int Immunol. 2000;12:909-914.
40. Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science. 1997;278:1626-1629.
41. Kawano T, Cui J, Koezuka Y, et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci USA. 1998;95:5690-5693.
42. Yue SC, Shaulov A, Wang R, et al. CD1d ligation on human monocytes directly signals rapid NF-κB activation and production of bioactive IL-12. Proc Natl Acad Sci USA. 2005;102:11811-11816.
43. van der Vliet HJ, Molling JW, von Blomberg BM, et al. The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin Immunol. 2004;112:8-23.
44. Metelitsa LS, Wu HW, Wang H, et al. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med. 2004;199:1213-1221.
45. Tachibana T, Onodera H, Tsuruyama T, et al. Increased intratumor Vα24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res. 2005;11:7322-7327.
46. Molling JW, Langius JA, Langendijk JA, et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol. 2007;25:862-868.
47. Giaccone G, Punt CJ, Ando Y, et al. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res. 2002;8:3702-3709.
48. Toura I, Kawano T, Akutsu Y, et al. Inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J Immunol. 1999;163:2387-2391.
49. +Vβ11 NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood. 2004;103:383-389.
50. Chang DH, Osman K, Connolly J, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosylceramide loaded mature dendritic cells in cancer patients. J Exp Med. 2005;201:1503-1517.
51. Ishikawa A, Motohashi S, Ishikawa E, et al. A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2005;11:1910-1917.
52. Motohashi S, Ishikawa A, Ishikawa E, et al. A phase I study of in vitro expanded NKT cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2006;12:6079-6086.
53. Lee PT, Benlagha K, Teyton L, et al. Distinct functional lineages of human Vα24 natural killer T cells. J Exp Med. 2002;195:637-641.
54. Gumperz JE, Miyake S, Yamamura T, et al. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med. 2002;195:625-636.
55. + NK T cells activated by α-galactosylceramide-pulsed monocyte-derived dendritic cells. J Immunol. 2002;158:3140-3144.
56. Crowe NY, Coquet JM, Berzins SP, et al. Differential antitumor immunity mediated by NKT cells subsets in vivo. J Exp Med. 2005;202:1279-1288.
57. Fujii S, Shimizu K, Hemmi H, et al. Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci USA. 2006;103:11252-11257.
58. + Tregs and NKT cells: regulators regulating regulators. Trends Immunol. 2006;27:322-327.
59. + T-regulatory cells and systemic collapse of antitumour immunity. Immunology. 2001;103:449-457.
60. + T regulatory 1 cells to suppress antitumor immunity. J Immunol. 2005;175:2931-2937.
61. Girardi M, Oppenheim DE, Steele CR, et al. Regulation of cutaneous malignancy by gamma delta T cells. Science. 2001;294:605-609.